Breaking News Instant updates and real-time market news.

BIIB

Biogen

$296.08

-20.91 (-6.60%)

08:52
02/15/18
02/15
08:52
02/15/18
08:52

Biogen enrollment increase is not unusual, says William Blair

William Blair analyst Matt Phipps believes increasing enrollment of Biogen's Phase III trials of aducanumab in prodromal Alzheimer's disease to ensure appropriate powering and confidence interval error margin, which caused yesterday's share selloff, is "prudent and not unusual." Based on his analysis, the trial is sufficiently powered to detect a benefit significantly below what was observed in the Phase Ib trial. The increase in variability in and of itself does not preclude trial success, Phipps tells investors in a research note. He sees "very limited" downside at current price levels if aducanumab were to fail, and adds that success of Biogen's growing earlier stage pipeline has the potential to provide additional upside. The analyst sees upside potential of over 50%, to $500 per share, if Phase III trials of aducanumab are successful, and a base support level slightly below $300 per share if the trials fail. Phipps keeps an Outperform rating on Biogen.

  • 08

    Mar

  • 30

    May

BIIB Biogen
$296.08

-20.91 (-6.60%)

02/07/18
PIPR
02/07/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen should be bought on any weakness, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying Biogen on any weakness following news that Tysabri's Action2 study in acute ischemic stroke failed to demonstrate a clinical benefit. Tysabri had failed once before in this setting, and the analyst notes he saw little reason for optimism on this study. Raymond says remains focused on the strength of Biogen's multiple sclerosis franchise, Spinraza, and the positive signals from Phase 1 studies in aducanumab. He keeps an Overweight rating on Biogen with a $407 price target.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $375
JEFF
Hold
Biogen swings back to Alzheimer's uncertainty, says Jefferies
At an industry conference today, Biogen provided some updates to its Phase III Alzheimer's study, including plans to add an additional 510 patients across the two aducanumab studies, Jefferies analyst Michael Yee tells investors in a research note. While these changes do not necessarily dramatically change the probability of success, it does change Wall Street's "sense of confidence," Yee contends. He believes the market will "swing back to uncertainty" on the Alzheimer's pendulum based on trial changes. Yee thinks Biogen needs to acquire de-risked "neuro/orphan companies" to "change the narrative" from being a binary Alzheimer's company to one with products even if Alzheimer's doesn't work. Yee keeps a Hold rating on Biogen shares with a $375 price target. The stock in afternoon trading is down 7% to $295.42.
02/15/18
PIPR
02/15/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using the selloff yesterday in shares of Biogen (BIIB) as a buying opportunity. The stock pulled back after management disclosed at a conference plans to up-size the Phase 3 aducanumab program by 510 patients total. While "this is a bit unnerving," particularly on the heels of another Phase 3 Alzheimer's failure for Merck's (MRK) verubecestat, the study remains blinded and variability on the primary endpoint can stem from a host of reasons, not all of them bad, Raymond tells investors in a research note titled "Aducanumab P3 Upsizing Doesn't Tell Us Much." The analyst does not think yesterday's news says much about the chances for an interim analysis or about aducanumab's efficacy profile. He keeps an Overweight rating on Biogen with a $407 price target.
02/15/18
ADAM
02/15/18
NO CHANGE
Target $350
ADAM
Hold
Biogen trial change does not alter efficacy assumptions, says Canaccord
Canaccord analyst Sumant Kulkarni noted Biogen announced an upsizing to its Alzheimer drug trial due to greater variability on the primary endpoint. The analyst said this was based on a pre-specified plan and does not change the efficacy assumptions of the drug. As a result he expects the shares to recover some of their losses. Kulkarni maintained his Hold rating and $350 price target on Biogen shares.

TODAY'S FREE FLY STORIES

BNFT

Benefitfocus

$49.88

-1.99 (-3.84%)

20:44
12/18/18
12/18
20:44
12/18/18
20:44
Hot Stocks
Benefitfocus sees FY19 revenue growth in 'mid-to-high teens' »

Sees FY19 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

AGCO

Agco

$56.59

2.7 (5.01%)

20:36
12/18/18
12/18
20:36
12/18/18
20:36
Earnings
Agco guides initial FY19 EPS ~$4.60, consensus $4.59 »

Sees FY19 revenue around…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

NVS

Novartis

$85.40

-0.4 (-0.47%)

20:28
12/18/18
12/18
20:28
12/18/18
20:28
Hot Stocks
Novartis announces licensing of pradigastat to Anji Pharmaceuticals »

Anji Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

SQ

Square

$59.91

1.28 (2.18%)

20:25
12/18/18
12/18
20:25
12/18/18
20:25
Recommendations
Square analyst commentary at Tigress Financial »

Square offers continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

PAYX

Paychex

$64.32

-0.63 (-0.97%)

, GIS

General Mills

$36.70

-0.03 (-0.08%)

20:25
12/18/18
12/18
20:25
12/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PAYX

Paychex

$64.32

-0.63 (-0.97%)

GIS

General Mills

$36.70

-0.03 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 19

    Dec

FSNUY

Fresenius SE

$0.00

(0.00%)

20:21
12/18/18
12/18
20:21
12/18/18
20:21
Upgrade
Fresenius SE rating change at Goldman Sachs »

Fresenius SE upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNFT

Benefitfocus

$49.88

-1.99 (-3.84%)

20:19
12/18/18
12/18
20:19
12/18/18
20:19
Recommendations
Benefitfocus analyst commentary at Jefferies »

Benefitfocus analyst day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FN

Fabrinet

$51.13

2.17 (4.43%)

20:06
12/18/18
12/18
20:06
12/18/18
20:06
Recommendations
Fabrinet analyst commentary at Piper Jaffray »

Fabrinet among the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$33.96

0.17 (0.50%)

19:38
12/18/18
12/18
19:38
12/18/18
19:38
Upgrade
Sealed Air rating change at BMO Capital »

Sealed Air upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$124.29

-0.2 (-0.16%)

19:31
12/18/18
12/18
19:31
12/18/18
19:31
Hot Stocks
Vice President of Caterpillar Excavation unit to step down »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$71.99

-2.01 (-2.72%)

19:10
12/18/18
12/18
19:10
12/18/18
19:10
Periodicals
Exxon tells EPA it opposes weakening Obama-era emissions rules, Reuters says »

Exxon Mobil issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

CBS

CBS

$46.21

-0.6 (-1.28%)

, DIS

Disney

$109.43

-1.2 (-1.08%)

19:07
12/18/18
12/18
19:07
12/18/18
19:07
Periodicals
CBS poised to ramp up CEO search after denying Moonves severance, Bloomberg says »

CBS's (CBS) board is…

CBS

CBS

$46.21

-0.6 (-1.28%)

DIS

Disney

$109.43

-1.2 (-1.08%)

FOX

21st Century Fox

$48.49

-0.29 (-0.59%)

FOXA

21st Century Fox

$48.78

-0.22 (-0.45%)

TRCO

Tribune Media

$45.25

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 05

    Feb

JBL

Jabil

$22.21

0.65 (3.01%)

, SCS

Steelcase

$14.19

0.02 (0.14%)

19:02
12/18/18
12/18
19:02
12/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Jabil…

JBL

Jabil

$22.21

0.65 (3.01%)

SCS

Steelcase

$14.19

0.02 (0.14%)

ADMS

Adamas Pharmaceuticals

$8.11

-0.67 (-7.63%)

ANGI

Angi Homeservices

$15.64

-0.01 (-0.06%)

MU

Micron

$34.12

0.23 (0.68%)

LRCX

Lam Research

$138.01

2.39 (1.76%)

AMAT

Applied Materials

$33.27

0.62 (1.90%)

FDX

FedEx

$185.01

2.81 (1.54%)

UPS

UPS

$97.25

0.33 (0.34%)

SURF

Surface Oncology

$7.35

-0.44 (-5.65%)

GSAT

Globalstar

$0.36

0.0082 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 18

    Dec

  • 19

    Dec

  • 08

    Jan

  • 19

    Dec

CBS

CBS

$46.21

-0.6 (-1.28%)

18:45
12/18/18
12/18
18:45
12/18/18
18:45
Periodicals
CBS poised to ramp up CEO search after denying Moonves severance, Bloomberg says »

CBS's board is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

AMTB

Mercantil Bank

$12.00

-0.3 (-2.44%)

18:41
12/18/18
12/18
18:41
12/18/18
18:41
Syndicate
Mercantil Bank 6.3M share IPO priced at $13.00 per share »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

QDEL

Quidel

$50.00

0.9 (1.83%)

18:39
12/18/18
12/18
18:39
12/18/18
18:39
Hot Stocks
Quidel receives CE Mark for Sofia 2 Lyme+ FIA for use with Sofia 2 instrument »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAOI

Applied Optoelectronics

$15.40

-1.73 (-10.10%)

, ACIA

Acacia Communications

$39.32

-0.53 (-1.33%)

18:34
12/18/18
12/18
18:34
12/18/18
18:34
Recommendations
Applied Optoelectronics, Acacia Communications, Cisco, Fabrinet, Finisar analyst commentary at Piper Jaffray »

Cisco's Luxtera deal…

AAOI

Applied Optoelectronics

$15.40

-1.73 (-10.10%)

ACIA

Acacia Communications

$39.32

-0.53 (-1.33%)

CSCO

Cisco

$44.05

-0.16 (-0.36%)

FN

Fabrinet

$51.13

2.17 (4.43%)

FNSR

Finisar

$21.57

0.005 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 04

    Mar

WGO

Winnebago

$19.96

-0.73 (-3.53%)

18:20
12/18/18
12/18
18:20
12/18/18
18:20
Hot Stocks
Winnebago to withdraw its Chicago Stock Exchange listing »

Winnebago Industrie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

CVS

CVS Health

$69.55

-1.12 (-1.58%)

, AET

Aetna

$0.00

(0.00%)

18:07
12/18/18
12/18
18:07
12/18/18
18:07
Periodicals
Judge weighs naming monitor to oversee CVS during court process, Reuters says »

Judge Richard Leon of the…

CVS

CVS Health

$69.55

-1.12 (-1.58%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FDX

FedEx

$185.01

2.81 (1.54%)

, AMZN

Amazon.com

$1,551.00

29.66 (1.95%)

18:05
12/18/18
12/18
18:05
12/18/18
18:05
Hot Stocks
FedEx sees no impact from Amazon's air freight ops »

FedEx (FDX) says it is…

FDX

FedEx

$185.01

2.81 (1.54%)

AMZN

Amazon.com

$1,551.00

29.66 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 19

    Dec

  • 20

    Dec

  • 04

    Jan

  • 07

    Jan

VZ

Verizon

$55.67

-0.29 (-0.52%)

18:04
12/18/18
12/18
18:04
12/18/18
18:04
Hot Stocks
Verizon Media Group will replace the Oath brand »

Oath COO Guru Gowrappan …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CE

Celanese

$85.39

0.98 (1.16%)

18:02
12/18/18
12/18
18:02
12/18/18
18:02
Hot Stocks
Celanese raises GUR and GHR grades engineered materials prices by 10% »

Celanese announced price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$185.01

2.81 (1.54%)

17:55
12/18/18
12/18
17:55
12/18/18
17:55
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FDX

FedEx

$185.01

2.81 (1.54%)

17:52
12/18/18
12/18
17:52
12/18/18
17:52
Hot Stocks
FedEx sees voluntary buyout saving company $225M-$275M in FY20 »

Sees 18-24 month payback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

VVV

Valvoline

$19.00

0.21 (1.12%)

17:51
12/18/18
12/18
17:51
12/18/18
17:51
Hot Stocks
Valvoline to open 17 acquired Quick-Lube centers in California »

Valvoline Inc. - a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.